טוען...
Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy
BACKGROUND: Ustekinumab is a new immunosuppressive anti-psoriasis agent. The drug targets the p40 subunit of IL-12 and IL-23 and indirectly inhibits cytokine production by Th17 cells. MAIN OBSERVATIONS: We present a case of a 36-year-old male patient with psoriasis, who received ustekinumab therapy,...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Specjalisci Dermatolodzy
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3157804/ https://ncbi.nlm.nih.gov/pubmed/21886740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3315/jdcr.2010.1041 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|